GNRD yields 2000000.00% · ABBV yields 3.12%● Live data
📍 GNRD pulled ahead of the other in Year 1
Combined, GNRD + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GNRD + ABBV for your $10,000?
General Datacomm Industries Inc., through its subsidiaries, designs, develops, manufactures, and markets high-speed network access and transport equipment to provide audio, video, and data transmissions. It offers DSLware and universal xDSL access systems to extend the copper loop, SNMP-based network management systems, IP dynamic mini-routers, TDM over IP gateways, routers and switches, modem security products, remote control/backup products for railroad wayside devices, broadband ATM/MPLS/hybrid/WAN solutions, remote network maintenance products, transportation and wireless connection application products, and blade adapters. It engages in implementations for distributed control systems, and supervisory control and data acquisition networks; and connectivity and internetworking for the healthcare industry. It offers USDA RUS accepted products, including hybrid multiservice access solutions, IP transport and switching products, integrated access devices to consolidate bandwidth requirements, modems/AES encryption products for high speed remote access, and CSUs/DSUs for narrowband and broadband access. It develops and sells infrastructure solutions to carriers and service providers of various types, including RBOCs, PTTs, IXCs, ILECs, IOCs, ISPs, and CLECs; and provides network installation, maintenance plan, extended warranty, operations, enterprise security management, network outsourcing, factory direct repair, and factory direct customer training services. The company's products enable network access, bandwidth management, multiprotocol label switching, voice over IP, Ethernet, and power over Ethernet. It serves carriers and service providers, governments, business enterprises, and commercial end-users in North America, Latin America, and internationally through distributors and resellers in the United States, Canada, Chile, Vietnam, the Russian Federation, and Hong Kong. The company was founded in 1969 and is headquartered in Naugatuck, Connecticut.
Full GNRD Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.